- Home
- UAA vs IMCR Comparison
UAA vs IMCR Comparison
Compare UAA & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAA
- IMCR
- Stock Information
- Founded
- UAA 1996
- IMCR 2008
- Country
- UAA United States
- IMCR United Kingdom
- Employees
- UAA N/A
- IMCR N/A
- Industry
- UAA Apparel
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UAA Consumer Discretionary
- IMCR Health Care
- Exchange
- UAA Nasdaq
- IMCR Nasdaq
- Market Cap
- UAA 2.2B
- IMCR 1.8B
- IPO Year
- UAA N/A
- IMCR 2021
- Fundamental
- Price
- UAA $4.85
- IMCR $35.24
- Analyst Decision
- UAA Hold
- IMCR Buy
- Analyst Count
- UAA 19
- IMCR 8
- Target Price
- UAA $6.97
- IMCR $57.00
- AVG Volume (30 Days)
- UAA 13.7M
- IMCR 290.9K
- Earning Date
- UAA 11-06-2025
- IMCR 11-05-2025
- Dividend Yield
- UAA N/A
- IMCR N/A
- EPS Growth
- UAA N/A
- IMCR N/A
- EPS
- UAA 0.23
- IMCR N/A
- Revenue
- UAA $5,114,713,000.00
- IMCR $356,145,000.00
- Revenue This Year
- UAA N/A
- IMCR $31.83
- Revenue Next Year
- UAA $2.69
- IMCR $8.50
- P/E Ratio
- UAA $21.38
- IMCR N/A
- Revenue Growth
- UAA N/A
- IMCR 26.78
- 52 Week Low
- UAA $4.78
- IMCR $23.15
- 52 Week High
- UAA $11.89
- IMCR $39.33
- Technical
- Relative Strength Index (RSI)
- UAA 31.62
- IMCR 56.75
- Support Level
- UAA $4.91
- IMCR $35.33
- Resistance Level
- UAA $5.05
- IMCR $37.16
- Average True Range (ATR)
- UAA 0.15
- IMCR 1.36
- MACD
- UAA 0.05
- IMCR 0.32
- Stochastic Oscillator
- UAA 12.26
- IMCR 53.39
About UAA Under Armour Inc.
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and elsewhere. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. The Baltimore-based company was founded in 1996 and is led by controlling shareholder Kevin Plank.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.